Payment overview · 2025
General Payments
$1,003.66
48 reported records · 20 companies
Healthcare provider profile · identity verified
John Parker Gerace, MD
Allopathic & Osteopathic Physicians|Family Medicine · WESTLAKE, OH · NPI 1356428478
Verified facts
What the public records show
CMS Open Payments records show John Parker Gerace, MD received $1,003.66 in general payments during 2025 across 48 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.01 | 17.8% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.87 | 10.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.09 | 8.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $82.58 | 8.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.66 | 6.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $63.91 | 6.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.76 | 6.2% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $52.42 | 5.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.70 | 3.8% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $34.36 | 3.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $33.52 | 3.3% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.65 | 3.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $31.25 | 3.1% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $24.84 | 2.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.85 | 2.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $20.89 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.40 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.08 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.32 | 1.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.50 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $998.11 | 47 |
| Education | $5.55 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $111.86 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $82.58 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $68.66 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $63.91 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.76 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.66 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.69 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $52.42 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.29 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.18 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.50 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $34.36 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $33.52 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $32.65 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.77 | 2 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $24.43 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.58 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 127 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
111 | 34 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
42 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 544 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 500 | 140 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 485 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 449 | 128 |
| Losartan Potassium | Losartan Potassium | 352 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 341 | 108 |
| Metformin Hcl | Metformin Hcl | 247 | 67 |
| Lisinopril | Lisinopril | 246 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 237 | 74 |
| Omeprazole | Omeprazole | 224 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 211 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 63 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 206 | 65 |
| Gabapentin | Gabapentin | 196 | 51 |
| Simvastatin | Simvastatin | 176 | 52 |
| Pioglitazone Hcl | Pioglitazone Hcl | 172 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 164 | 48 |
| Meloxicam | Meloxicam | 152 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 46 |
| Furosemide | Furosemide | 143 | 36 |
| Prednisone | Prednisone | 143 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 43 |
| Ozempic | Semaglutide | 131 | 27 |
| Eliquis | Apixaban | 127 | 32 |
| Mirtazapine | Mirtazapine | 122 | 38 |
| Allopurinol | Allopurinol | 117 | 38 |
| Glimepiride | Glimepiride | 117 | 30 |
| Donepezil Hcl | Donepezil Hcl | 116 | 35 |
| Synthroid | Levothyroxine Sodium | 111 | 34 |
| Sertraline Hcl | Sertraline Hcl | 108 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 36 |
| Atenolol | Atenolol | 103 | 28 |
| Trazodone Hcl | Trazodone Hcl | 98 | 35 |
| Pregabalin | Pregabalin | 93 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 22 |
| Tramadol Hcl | Tramadol Hcl | 83 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 25 |
| Famotidine | Famotidine | 76 | 30 |
| Bupropion Xl | Bupropion Hcl | 74 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 21 |
| Xarelto | Rivaroxaban | 73 | 17 |
| Metformin Hcl Er | Metformin Hcl | 70 | 19 |
| Colchicine | Colchicine | 69 | 21 |
| Mounjaro | Tirzepatide | 67 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 17 |
| Memantine Hcl | Memantine Hcl | 66 | 18 |
| Azithromycin | Azithromycin | 65 | 59 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 12 |
| Alendronate Sodium | Alendronate Sodium | 61 | 14 |
| Rybelsus | Semaglutide | 57 | 12 |
| Montelukast Sodium | Montelukast Sodium | 54 | 18 |
| Jardiance | Empagliflozin | 52 | 14 |
| Trulicity | Dulaglutide | 52 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 51 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 11 |
| Potassium Chloride | Potassium Chloride | 49 | 19 |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 47 | 18 |
| Primidone | Primidone | 46 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 32 |
| Repatha Syringe | Evolocumab | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 42 |
| Alprazolam | Alprazolam | 41 | 21 |
| Aripiprazole | Aripiprazole | 40 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 37 |
| Finasteride | Finasteride | 38 | 13 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Carvedilol | Carvedilol | 37 | 12 |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Valsartan | Valsartan | 34 | 11 |
| Spironolactone | Spironolactone | 33 | 12 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 18 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Celecoxib | Celecoxib | 27 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 26 |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 21 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | 14 |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 12 |
| Clarithromycin | Clarithromycin | 16 | 15 |
| Clonazepam | Clonazepam | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 13 | 13 |
| Telmisartan | Telmisartan | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,003.66 · 48 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, Azstarys, BEXSERO, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, Fibroscan, GEMTESA, Kerendia, Korlym, NURTEC ODT, OTEZLA, Ohtuvayre, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, SHINGRIX, TRINTELLIX, UBRELVY, VRAYLAR, Veozah, WATCHMAN Access System, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error